DNA Methylation and mRNA Expression of B7-H3 Gene in Ankylosing Spondylitis: A Case-Control Study

Chen, Yuting; Wu, Ye; Yang, Hui; Wang, Jinian; Kong, Jiangping; Yu, Lingxiang; Ni, Man; Deng, Yujie; Xu, Shengqian; Yu, Haiyang; Shuai, Zongwen; Pan, Faming

doi:10.1080/08820139.2022.2095285

Cited by 6 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activation of p38 MAPK-eIF4E signaling axis serves as a key regulator of transcription initiation and protein expression of B7-H3 in tumor cells [51]. Recently, B7-H3 gene promotor was found to be hypomethylated in ankylosing spondylitis patients, whereas B7-H3 expression was significantly elevated, suggesting that B7-H3 gene is under epigenetic control [52].…”

Section: Regulation Of B7-h3 Expressionmentioning

confidence: 99%

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development

et al. 2023

View full text Add to dashboard Cite

B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked to tumor cell proliferation, metastasis, and therapeutic resistance. Furthermore, its drastic difference in protein expression levels between normal and tumor tissues suggests that targeting B7-H3 with drugs would lead to cancer-specific toxicity, minimizing harm to healthy cells. These properties make B7-H3 a promising target for cancer therapy.Recently, important advances in B7-H3 research and drug development have been reported, and these new findings, including its involvement in cellular metabolic reprograming, cancer stem cell enrichment, senescence and obesity, have expanded our knowledge and understanding of this molecule, which is important in guiding future strategies for targeting B7-H3. In this review, we briefly discuss the biology and function of B7-H3 in cancer development. We emphasize more on the latest findings and their underlying mechanisms to reflect the new advances in B7-H3 research. In addition, we discuss the new improvements of B-H3 inhibitors in cancer drug development.

show abstract

Section: Regulation Of B7-h3 Expressionmentioning

confidence: 99%

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development

et al. 2023

View full text Add to dashboard Cite

show abstract

“…AS affects approximately 0.1%–0.5% of the general population worldwide ( 2 ). Although the nosogenesis of AS remains largely unknown, numerous evidence has revealed that the interactions of genetic inheritance, environmental exposure, chronic infections, and abnormal endocrine contribute to the occurrence and development of the disease ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Genetically predicted ankylosing spondylitis is causally associated with psoriasis

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundPrevious observational studies have reported the striking association between ankylosing spondylitis (AS) and psoriasis, but the causal relationship between the two diseases remains unclear.MethodsTwo-sample Mendelian randomization (MR) analysis with methods of inverse-variance weighted, MR-Egger regression, weighted median, and weighted mode was conducted to evaluate the bidirectional causal associations between AS and psoriasis. Effective single-nucleotide polymorphisms (SNPs) from genome-wide association studies (GWAS) were selected as instrumental variables (IVs). Sensitivity analyses were also applied to verify whether heterogeneity and pleiotropy can bias the results.ResultWe found positive causal effects of genetically increased AS risk on psoriasis (IVW: OR = 1.009, 95% CI = 1.005–1.012, p = 8.07E-07). Comparable outcomes were acquired by MR-Egger regression, weighted median, and weighted mode approaches. Nevertheless, we did not find significant causal effects of psoriasis on AS (IVW: OR = 1.183, 95% CI = 0.137–10.199, p = 0.879). The sensitivity analyses showed that the horizontal pleiotropy was unlikely to skew the causality. The leave-one-out analysis demonstrated that no single SNP can drive the MR estimates. No evidence of heterogeneity was found between the selected IVs.ConclusionOur findings provide evidence that AS has positive causal effects on the risk of psoriasis in the European population.

show abstract